Vir Bio (VIR) Revenue & Revenue Breakdown
Vir Bio Revenue Highlights
Latest Revenue (Y)
$74.20M
Latest Revenue (Q)
$2.38M
Main Segment (Y)
Contract Revenue
Main Geography (Y)
Non-US
Vir Bio Revenue by Period
Vir Bio Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $74.20M | -13.90% |
2023-12-31 | $86.18M | -94.55% |
2022-12-31 | $1.58B | 45.39% |
2021-12-31 | $1.09B | 1516.58% |
2020-12-31 | $67.25M | 9357.81% |
2019-12-31 | $711.00K | -18.09% |
2018-12-31 | $868.00K | 482.55% |
2017-12-31 | $149.00K | - |
Vir Bio generated $74.20M in revenue during NA 2024, up -13.90% compared to the previous quarter, and up 10436.71% compared to the same period a year ago.
Vir Bio Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $2.38M | -22.60% |
2024-06-30 | $3.08M | -94.55% |
2024-03-31 | $56.38M | 235.83% |
2023-12-31 | $16.79M | -509.64% |
2023-09-30 | $-4.10M | -67.79% |
2023-06-30 | $-12.72M | -127.23% |
2023-03-31 | $46.71M | 114.38% |
2022-12-31 | $21.79M | -94.13% |
2022-09-30 | $371.43M | -970.13% |
2022-06-30 | $-42.69M | -103.47% |
2022-03-31 | $1.23B | 51.89% |
2021-12-31 | $809.76M | 688.37% |
2021-09-30 | $102.71M | -40.96% |
2021-06-30 | $173.99M | 28658.02% |
2021-03-31 | $605.00K | 101.00% |
2020-12-31 | $301.00K | 60.11% |
2020-09-30 | $188.00K | -99.72% |
2020-06-30 | $66.27M | 13507.60% |
2020-03-31 | $487.00K | 31.27% |
2019-12-31 | $371.00K | 56.54% |
2019-09-30 | $237.00K | 175.58% |
2019-06-30 | $86.00K | 405.88% |
2019-03-31 | $17.00K | 183.33% |
2018-12-31 | $6.00K | -94.74% |
2018-09-30 | $114.00K | -95.10% |
2018-06-30 | $2.33M | - |
2018-03-31 | $2.33M | - |
Vir Bio generated $2.38M in revenue during Q3 2024, up -22.60% compared to the previous quarter, and up -18.71% compared to the same period a year ago.
Vir Bio Revenue Breakdown
Vir Bio Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
---|---|---|---|---|---|
Grant | $10.49M | $46.69M | - | - | - |
Collaboration Revenue | $8.38M | $37.27M | $1.51B | $917.19M | - |
Contract Revenue | $55.33M | $2.23M | $52.71M | $169.87M | - |
License Revenue | - | - | - | - | - |
License | - | - | $22.29M | - | $22.75M |
Vir Bio's latest annual revenue breakdown by segment (product or service), as of Dec 24: Contract Revenue (74.57%), Grant (14.14%), and Collaboration Revenue (11.29%).
Quarterly Revenue by Product
Product/Service | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Contract Revenue | $865.00K | $1.39M | $886.00K | $52.19M | $744.00K | $289.00K | $1.06M | $138.00K | $180.00K | $40.00M | $12.25M | $282.00K | $293.00K | $315.00K | $605.00K | - | - | - | - | - |
Grant | $1.10M | $2.09M | $2.13M | $5.17M | $23.43M | $6.74M | $16.52M | $200.00K | - | - | - | - | - | - | - | - | - | - | - | - |
Collaboration Revenue | $8.32M | $55.00K | - | $-4.39M | $46.57M | $21.61M | $309.14M | $-54.94M | $1.23B | $809.46M | $102.40M | $5.33M | - | - | - | - | - | - | - | - |
License Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
License | - | - | - | - | - | - | - | - | - | $22.29M | - | - | - | - | $22.75M | - | - | - | - | - |
Vir Bio's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (80.93%), Grant (10.66%), and Contract Revenue (8.41%).
Vir Bio Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 24 |
---|---|
Non-US | $60.31M |
UNITED STATES | $11.53M |
Vir Bio's latest annual revenue breakdown by geography, as of Dec 24: Non-US (83.96%), and UNITED STATES (16.04%).
Vir Bio Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
PTCT | PTC Therapeutics | $806.78M | $135.42M |
BPMC | Blueprint Medicines | $508.82M | $128.18M |
KRYS | Krystal Biotech | $290.51M | $83.84M |
MDGL | Madrigal Pharmaceuticals | $180.13M | $62.17M |
DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
AMLX | Amylyx Pharmaceuticals | $87.37M | $416.00K |
VIR | Vir Bio | $74.20M | $2.38M |
CVAC | CureVac | $52.70M | $12.37M |
AKRO | Akero Therapeutics | - | - |
VKTX | Viking Therapeutics | - | - |
TERN | Terns Pharmaceuticals | - | - |